background: The incidence of mismatch repair (MMR) deficiency in young colorectal cancers (CRC) remains unknown in Asians. This preliminary study assessed the clinicopathological features and efficacy of screening for MMR protein deficiency in young Asian CRC patients. , patients under the age of 50 with immunohistochemical (IHC) staining for MMR proteins in resected CRC specimens were retrieved from a prospective computerised database.
IntRoDuCtIon
Hereditary non-polyposis colorectal cancer (HNPCC), also known as Lynch syndrome (LS), is the most common of the hereditary colorectal cancer syndromes, accounting for 1-5% of all colorectal cancers [1] [2] [3] . HNPCC is an autosomal dominant hereditary condition due to germline mutations in any of the 5 DNA mismatch repair genes (MMR) 4, 5 , including MLH1 6,7 , MSH2 8, 9 , MSH6 10 , and less frequently, PMS1 and PMS2 11 . Defective mismatch repair leads to expansion or contraction of short repeated sequences of DNA, a phenomenon known as microsatellite instability (MSI) 12 . Mutations in the MMR genes also lead to loss of immunohistochemical (IHC) staining of their protein products, providing a potentially cost effective means of screening for possible HNPCCrelated cancers.
Phenotypically, HNPCC is characterised by an early onset of colorectal cancers (CRC) (mean age of approximately 45 years) and by the development of extra-colonic cancers in the endometrium, ovary, stomach, small bowel, pancreas, hepatobiliary tract, Proceedings of Singapore Healthcare  Volume 19  Number 1  2010 brain, and upper uroepithelial tract [13] [14] [15] . However, the penetrance of these MMR gene defects is approximately 80% 16 and these phenotypic features may not be manifested in an individual with HNPCC in its entirety. The use of Amsterdam Criteria I and II for clinical diagnosis of HNPCC has inherent flaws, with sensitivity and specificity ranging from 54-91% and 62-84% respectively 17 . Hence, reliance on clinical criteria alone for case identification will likely lead to under-diagnosis of HNPCC cases. Furthermore, two Asian studies 18, 19 suggested that Asian HNPCC may have a propensity for left-sided colorectal cancers in their kindreds, a distinctly different phenotypic expression compared to the Caucasians 20, 21 . It is therefore difficult to distinguish HNPCC-related CRCs from young sporadic CRCs in the Asian population without further objective testing.
In this study, we examined the use of IHC staining of MMR proteins as a screening strategy for HNPCC diagnosis in a cohort of unselected young Asian CRC patients, and report on their corresponding clinicopathological features.
MAteRIAlS AnD MethoDS Subjects
The study protocol was approved by the Institutional Review Board of the Singapore General Hospital (SGH) and the study cohort was retrospectively identified from the Singapore Polyposis Registry 22 . This Registry was established in 1989 as a central nationwide registry for all high-risk colorectal cancers and relied on notifications from clinicians. Data is collected prospectively and the registry would in turn verify census information and death notifications in a comprehensive computerised database containing clinical and pathological information. In this study, all young CRC patients who underwent surgical resection in SGH between January 2006 and October 2009 who fulfilled the following inclusion criteria were analysed: (1) age 50 years or younger at the time of CRC diagnosis;
(2) patients who underwent surgical resection for newly diagnosed histological confirmed CRC; and (3) patients whose tumour specimens had IHC staining for MMR proteins. Patients who presented with recurrent cancer, Inflammatory Bowel Disease, Familial Adenomatous Polyposis or other polyposis syndromes were excluded.
The location of the index CRC was considered a right-sided lesion if it arose proximal to the splenic flexure. Lesions at or distal to the splenic flexure were thus considered left-sided. Pre-operative staging included Computerised Tomography (CT) scanning of the abdomen and pelvis. Rectal tumours were additionally staged with magnetic resonance imaging (MRI) or endorectal ultrasound where feasible. Pre-operatively, all patients underwent complete colonoscopy to exclude synchronous cancers. Obstructive lesions that precluded a complete endoscopic evaluation of the colon were evaluated for synchronous lesions using CT colonography or barium enema pre-operatively. A completion colonoscopy was performed within 6 months of surgery for those whom a complete colonoscopy was not possible pre-operatively. Any colonic tumour diagnosed at the same time as the index lesion or within one year of the surgery was considered "synchronous" while those that were discovered after one year were defined as "metachronous" lesions. In the case of synchronous lesions, the most advanced lesion was used for tumour stage classification comparisons.
Staging of disease was according to AJCC Cancer Staging Manual, 6th edition 23 after surgical resection, and comprises information from histological review of the resected specimen and radiological investigations of distant metastases. Pathologic features such as mucin, signet cells, perineural and lymphovascular invasion were assessed. Family history was obtained via routine clinical interviews during admission for surgery. For patients with family histories suggestive of HNPCC according to Amsterdam I and II criteria (see Table 1 ), further detailed pedigree data were obtained by a genetic counsellor via telephone or face-to-face interviews with the patients and their relatives.
Immunohistochemical Staining
IHC staining was routinely offered to all patients ≤50 years old undergoing elective resection for CRC. IHC was performed using the standard streptavidin-biotin-peroxidase procedure. Specifically, 5-µm thick sections of 10% formalinfixed, paraffin embedded tumour or tissue were first de-paraffinized in xylene, rehydrated in graded alcohols, and washed in double-distilled water. Endogenous peroxidase activity was blocked by incubation with 3% H 2 O 2 . The slides were then placed in 10 mM citrate buffer at pH 6 and boiled in a microwave for 15 minutes for antigen retrieval. After treatment with 10% normal goat serum for 10 minutes to block nonspecific protein binding, primary monoclonal antibodies against MLH1 (clone G168-728, diluted 1:250, PharMingen, San Diego, CA), MSH2 (clone FE11, diluted 1:50, Oncogene Research Products, Cambridge, MA), and MSH6 (clone GRBP.P1/2.D4, diluted 1:200; Serotec Inc, Raleigh, NC) were applied. Antigen-antibody reaction was visualised using the avidin-biotinylated horseradish peroxidase complex (LSAB kit, Dako) and diaminobenzidine as the chromogen. Slides were counterstained with hematoxylin. Normal colonic crypt epithelium adjacent to the tumour, lymphoid, and stromal cells served as internal positive controls for staining. Appropriate external positive (normal colon mucosa) and negative (MSI tumours known to lack MLH1 or MSH2 protein expression) controls were used.
Pathology Review
All specimens with IHC staining were reviewed by a dedicated pathologist. Tumours that showed presence of diffuse nuclear staining were scored "Normal" for expression of that protein. Tumours were scored "Abnormal" if any of the following staining patterns were identified: (1) no nuclear staining/negative; (2) weak nuclear staining/ weak positive; (3) equivocal /inconclusive due to either strong or weak, diffuse cytoplasmic staining without diffuse strong nuclear staining.
Statistical Analysis
Statistical analysis was performed using the Statistical Package for Social Sciences version 16.0 (SPSS® Inc, Chicago, Illinois). Continuous data were summarised as mean and standard variations. Categorical data were described as raw numbers and percentages. Categorical variables were compared using Chi-square test (x 2 ) or Fisher's Exact Test where appropriate. P values less than 0.05 were considered statistically significant. Using all data, multiple logistic regression was used to measure the association between abnormal IHC and each of the clinic-pathological features.
ReSultS

Patient Characteristics
During the study period, 80 unrelated patients had their resected tumour specimens subjected to IHC staining. This was out of a total number of 250 patients ≤50 years old operated in the study period. The demographic and clinicopathologic characteristics are detailed in Table 2 (overleaf ). In the study cohort, there were 54% (n=43) males and 46% (n=37) females with a median age of 41years (interquartile range . The predominant ethnic group were Chinese at 80% (n=64), with the rest compromising of 10% Malays (n=8), 4% Indians (n=3) and 6% other races (n=5), reflecting the multiracial demographics of the country. In this 
tumour Characteristics
Sixty-four per cent (n=51) majority of the study cohort presented at an advanced stage (stages III and IV, see Table 3 , overleaf ). There were 8 (10%) Stage I patients, 21 (26%) Stage II patients, 36 (45%) Stage III patients and 15 (19%) Stage IV patients. Tumours were located predominantly on the left side (80%) with the most common cancer occurring in the rectum (38%), followed by the sigmoid colon (26%) and transverse colon (11%). (Fig. 1 ) One patient had associated synchronous tumours and was classified as having "right-sided" tumours as both tumours were located proximal to the splenic flexure. 86% (n=69) presented with locally advanced (T3 or T4) T stage tumours and 61% (n=49) had lymph node metastasis. Perineural invasion and vascular tumour emboli were present in 29% (n=23) and 35% (n=28) respectively. There was presence of mucin or signet ring cells in 12% (n=9) of the tumours and 9% (n=7) were poorlydifferentiated tumours. Moderately differentiated lesions were the most common (81%, n=65). In this cohort, we observed that left-sided lesions presented at a significantly higher stage of disease (Stage III and IV) as compared to right-sided lesions (69% vs 43%, p=0.04). There was, however, no significant differences in T stage, N stage or tumour differentiation when analysed by site of lesion.
Overall, abnormal IHC staining involving at least one of the 3 MMR proteins tested was observed in 23% (n=18) of the study cohort. Interestingly, the majority of those with abnormal IHC staining were left-sided tumours (13 left-sided vs 5 right-sided). The most common abnormal IHC stain was for MLH1 proteins at 18% (n=15), followed by MSH6 (6%, n=5) and MSH2 (2%, n=2) (see Table I ). Of the 15 patients who had abnormal staining of MLH1 (11 complete loss, 4 weakly positive stains), 3 had concomitant equivocal staining for MSH6. One tumour specimen had abnormal staining in all 3 proteins. Comparative analysis was performed between 2 subgroups according to IHC staining ( Table 3 , overleaf ). There were no demographic differences in gender, race or age group. Similarly, there was no increase in mucinous component, poor tumour differentiation, advanced T or tumour stage with abnormal MMR staging.
Family history
There were 8 patients that fulfilled either Amsterdam I or II criteria. Five of these patients had abnormal staining in 1 of the 3 MMR proteins Proceedings of Singapore Healthcare  Volume 19  Number 1  2010 (Fig. 2) . The family history of one patient could not be ascertained as he was adopted as an infant, although he was found to have equivocal staining for MLH1. Patients who fulfilled Amsterdam criteria were more likely to have abnormal IHC (28% vs 5%, p=0.04). However, if Amsterdam criteria alone were to be used, 72% (n=13) of the cohort with MMR staining abnormalities would have been missed.
A stepwise logistic regression was done to investigate the independent predictors for abnormal IHC staining. Factors considered for inclusion in the model were gender, age, family history suggestive of Amsterdam criteria, site of lesion (left or right), presence of mucinous tumour, pT stage, pN stage and AJCC stage. The entry criteria for variable entry into and exit from the model were p<0.05 and > 0.10 respectively. Multivariate analysis reveals that family history is the only significant predictive factor for defective MMR detection (OR 8.06, 95% CI 1.69-38.35, p=0.002).
DISCuSSIon
Our study reports a series of 80 unrelated young CRC patients (≤50 years), for whom IHC staining was performed. To our knowledge, this is the first study examining the use of IHC staining of MMR proteins for HNPCC screening in an unselected cohort of young Asian colorectal cancer patients.
Traditionally, clinical criteria such as the Amsterdam I/II and Bethesda criteria have been established to guide further gene testing in the diagnosis of Lynch syndrome and in identifying high-risk patients and families in the clinical setting and is useful in facilitating comparison between research studies [24] [25] [26] .While these guidelines are useful tools, the flaws of using these criteria are well known with limited sensitivity and specificity 17 . In addition, these criteria were established based on Caucasian populations, and may not be appropriate when applied to an Asian population as phenotypic, molecular and histopathological features may vary between different ethnic groups. Routine MSI testing in familial and sporadic CRC is expensive, labour intensive, requires expert pathologic examination, microdissection and amplification of a panel of genetic markers. Although it has become cheaper and easier to perform and is a highly sensitive indicator of defective mismatch repair, it needs to be complemented by germline testing for the offending MMR gene defect in cases of MSI-H and would require genetic counselling of affected individuals. Such services may not be widely available. At present, it remains unclear whether any one set of criteria can be applied uniformly to distinct populations likely to have different genetic and environmental risks. 18 We found that amongst the 18 cases with abnormal IHC staining, only 5 patients (28%) fulfilled Amsterdam Criteria. In fact, one of those with abnormal IHC staining was adopted as an infant, and Amsterdam Criteria would have been unrevealing with regard to his HNPCC risks. Although in this study, only 3 MMR proteins (namely hMLH1, hMSH2 and hMSH6) were tested in the tumour specimens, 23% (18 patients) showed abnormal staining in at least one of the 3 MMR proteins. This is likely to be an underestimate and it remains to be seen if the addition of IHC staining for PMS1 and PMS2 will increase this yield. Nonetheless, despite the limited sample size in this study, it appears that at least a substantial portion (23%) of our young CRC cases may be MMR-related and possible HNPCC. This needs to be further confirmed on larger scale studies incorporating the use of PMS1 and PMS2 testing, validated by MMR gene sequencing to truly determine the actual incidence and mutation profile of germline MMR deficiencies in our population. This study also highlighted the difficulty in using family history as a guide for a selection tool in screening for HNPCC. In Singapore, we observed a tendency towards smaller family sizes, hence Amsterdam Criteria which relied on the determination of the number of affected individuals in each family may not be useful. Furthermore, the largely migrant population with limited genealogical data meant that collection of accurate data concerning a family's cancer history is often difficult and unreliable. As a result, routine IHC screening may be necessary in all patients with young CRC in Singapore to improve our detection of HNPCC.
Interestingly, the majority of the tumours in this small study with abnormal IHC staining were located in the left colon (72% vs 28%), with the highest frequency in the rectum and sigmoid (64%). With this small sample size, we are not able to provide conclusive evidence that MMR defects primarily have a left-sided predominance; it does however provide suggestion once again that there may be a biologic difference in Asian populations and a larger sample size will be necessary to elucidate this difference. Nonetheless, the current recommendation of performing a total colectomy leaving the patient with an ileo-rectal anastomosis may not adequately address the segment of bowel at highest risk of cancer (namely the rectum and sigmoid). Moreover, the frequent occurrence of the index cancer in the rectum necessitates an Anterior Resection in most cases and for those with low rectal cancers, an ileo-anal pouch would have to be performed if a complete removal of all colonic mucosa were to be pursued as a risk reduction strategy. Further elucidation of the mutation profile of Asian HNPCC-related CRCs in larger numbers will certainly clarify the optimal surgical approach.
There are inherent limitations in our small preliminary series. IHC staining was not able to be performed for all patients operated in the duration of study as this review was not done on a trial basis. This included cases that were performed as emergencies and patients that declined IHC testing for various social and financial reasons. Nonetheless, despite the relatively small numbers in our dataset, the high incidence of abnormal IHC certainly provide impetus for us to continue screening all patients ≤50 years with CRC in our population. With successful implementation of intensive clinical surveillance in these high risk families, it is likely that precursor lesions such as polyps will be removed at a premalignant stage, making it much more difficult for these families to ever fulfil the Amsterdam Criteria. Reliance on molecular diagnostics must therefore be a cornerstone in the effective management of these high risk families.
ConCluSIon
Current literature has demonstrated that IHC staining of MMR proteins for HNPCC screening is a convenient, rapid and cost-effective approach 28, 29 .
We have shown in this small preliminary series that the use of IHC staining of at least 3 MMR proteins is a useful screening strategy for HNPCC diagnosis in Proceedings of Singapore Healthcare  Volume 19  Number 1  2010 a cohort of unselected young Asian CRC patients. MMR deficiency by IHC is noted in up to 23% of young CRCs. This may narrow the number of cases that require germline mutation studies. The use of Amsterdam criteria for selection of cases for screening may not be suitable in an Asian population. Routine screening of mismatch repair deficiency may be recommended for all young Asian CRC patients. Further validation in larger numbers incorporating MMR gene sequencing is required to clarify the optimal clinical protocol for HNPCC diagnosis and their subsequent surgical management.
